JP Morgan Chase
SNDX icon

JP Morgan Chase’s Syndax Pharmaceuticals SNDX Stock Holding History

JP Morgan Chase’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.81M Sell
258,519
-119,985
-32% -$2.61M ﹤0.01% 3181
2025
Q4 		$7.95M Buy
378,504
+124,654
+49% +$2.17M ﹤0.01% 2901
2025
Q3 		$3.91M Sell
253,850
-19,024
-7% -$249K ﹤0.01% 3575
2025
Q2 		$2.56M Sell
272,874
-832,933
-75% -$9.17M ﹤0.01% 3727
2025
Q1 		$13.6M Buy
1,105,807
+208,490
+23% +$2.94M ﹤0.01% 2273
2024
Q4 		$11.9M Buy
897,317
+269,638
+43% +$4.61M ﹤0.01% 2532
2024
Q3 		$12.1M Sell
627,679
-2,201
-0.3% -$45.5K ﹤0.01% 2448
2024
Q2 		$12.9M Sell
629,880
-52,584
-8% -$1.1M ﹤0.01% 2224
2024
Q1 		$16.2M Sell
682,464
-98,466
-13% -$2.2M ﹤0.01% 2059
2023
Q4 		$16.9M Buy
780,930
+51,832
+7% +$797K ﹤0.01% 1986
2023
Q3 		$10.6M Sell
729,098
-41,623
-5% -$787K ﹤0.01% 2195
2023
Q2 		$16.1M Buy
770,721
+221,636
+40% +$4.61M ﹤0.01% 1861
2023
Q1 		$11.6M Buy
549,085
+10,959
+2% +$273K ﹤0.01% 2154
2022
Q4 		$13.7M Sell
538,126
-78,125
-13% -$1.82M ﹤0.01% 1980
2022
Q3 		$14.8M Buy
616,251
+21,949
+4% +$492K ﹤0.01% 1819
2022
Q2 		$11.4M Buy
594,302
+354,473
+148% +$5.9M ﹤0.01% 2045
2022
Q1 		$4.17M Buy
239,829
+69,356
+41% +$1.17M ﹤0.01% 3168
2021
Q4 		$3.73M Buy
170,473
+95,491
+127% +$1.76M ﹤0.01% 3303
2021
Q3 		$1.43M Buy
74,982
+55,433
+284% +$924K ﹤0.01% 4041
2021
Q2 		$335K Buy
19,549
+7,831
+67% +$143K ﹤0.01% 4949
2021
Q1 		$262K Sell
11,718
-20,763
-64% -$469K ﹤0.01% 5036
2020
Q4 		$722K Buy
32,481
+22,439
+223% +$465K ﹤0.01% 4156
2020
Q3 		$141K Buy
10,042
+926
+10% +$14.1K ﹤0.01% 4541
2020
Q2 		$135K Sell
9,116
-52,143
-85% -$794K ﹤0.01% 4445
2020
Q1 		$672K Buy
61,259
+14,324
+31% +$134K ﹤0.01% 3665
2019
Q4 		$412K Buy
46,935
+10,580
+29% +$77.7K ﹤0.01% 4333
2019
Q3 		$271K Buy
36,355
+30,833
+558% +$281K ﹤0.01% 4481
2019
Q2 		$50K Buy
5,522
+1,902
+53% +$13.9K ﹤0.01% 5168
2019
Q1 		$19K Buy
3,620
+40
+1% +$228 ﹤0.01% 5424
2018
Q4 		$16K Sell
3,580
-7,039
-66% -$38.6K ﹤0.01% 5360
2018
Q3 		$86K Sell
10,619
-266,543
-96% -$1.9M ﹤0.01% 5007
2018
Q2 		$1.95M Sell
277,162
-149,779
-35% -$1.47M ﹤0.01% 3436
2018
Q1 		$6.08M Buy
426,941
+21,581
+5% +$229K ﹤0.01% 2409
2017
Q4 		$3.55M Sell
405,360
-14,310
-3% -$142K ﹤0.01% 2950
2017
Q3 		$4.97M Sell
419,670
-19,400
-4% -$238K ﹤0.01% 2572
2017
Q2 		$6.13M Buy
439,070
+435,207
+11,266% +$4.97M ﹤0.01% 2342
2017
Q1 		$53K Sell
3,863
-6,322
-62% -$65.6K ﹤0.01% 4513
2016
Q4 		$73K Buy
+10,185
New +$112K ﹤0.01% 4472
2016
Q3 		– Sell
-505
Closed -$5K – 4778
2016
Q2 		$5K Buy
+505
New +$6.92K ﹤0.01% 4459

Other funds holding SNDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

JP Morgan Chase's SNDX Position: Q1 2026 in Review

JP Morgan Chase reduced its Syndax Pharmaceuticals (SNDX) stake by 32% in Q1 2026, selling an estimated $2.61M and leaving 258,519 shares worth $5.81M. The position accounts for ﹤0.01% of the portfolio, ranked #3181.

JP Morgan Chase first reported a position in SNDX in Q2 2016 and has held it in 39 quarters since. The position peaked at $16.9M in Q4 2023. 246 funds tracked by Wall St. Rank hold SNDX as of Q1 2026.

  • JP Morgan Chase held 258,519 shares of Syndax Pharmaceuticals worth $5.81M as of Q1 2026.
  • JP Morgan Chase sold 119,985 Syndax Pharmaceuticals shares in Q1 2026, an estimated $2.61M.
  • Syndax Pharmaceuticals made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #3181 holding.
  • JP Morgan Chase first reported a position in Syndax Pharmaceuticals in Q2 2016 and has held it in 39 quarters since.
  • JP Morgan Chase's Syndax Pharmaceuticals position peaked at $16.9M in Q4 2023.
  • 246 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.